The Systemic Lupus Erythematosus Infection Predictive Index (LIPI): A Clinical-Immunological Tool to Predict Infections in Lupus Patients.
Torres-Ruiz. Jiram J; Mejía-Domínguez. Nancy R NR; Zentella-Dehesa. Alejandro A; Ponce-de-León. Alfredo A; Morales-Padilla. Sandra Rubí SR; Vázquez-Rodríguez. Ricardo R; Alvarado-Lara. Mario René MR; Reyna-de-la-Garza. Roberto Adrián RA; Tapia-Rodríguez. Miguel M; Juárez-Vega. Guillermo G; Merayo-Chalico. Javier J; Barrera-Vargas. Ana A; Alcocer-Varela. Jorge C JC; Gómez-Martín. Diana D
Key Findings
- Higher Th17 cells, low B cells, low TLR2 on monocytes, and cyclophosphamide use raise infection risk in lupus.
- Infected patients showed more low‑density granulocytes and higher LL‑37 levels in NETs.
- A composite index >1.5 predicted infection with 100% specificity and an AUC of 0.97.
Practical Outcomes
- For most biohackers, this study offers limited direct action because it focuses on a specific disease (SLE) and uses clinical lab tests not easily done at home. It does highlight that LL‑37 levels rise during infection, which might interest those tracking innate immunity, but there are no clear dosage or supplementation recommendations.
Summary
Researchers created a score that predicts which lupus patients are likely to get infections in the next year. The score uses immune cell counts, a gene marker (TLR2), and whether the patient is on cyclophosphamide. They also found that patients who got infections had more of a protein called LL-37 in their immune traps (NETs).
Abstract
Among autoimmune diseases, systemic lupus erythematosus (SLE) patients have a unique predisposition to develop infections, which represents one of their main causes of morbidity and mortality. Many infections occur at disease diagnosis in the absence of immunosuppressive therapy, suggesting that the immunological abnormalities in SLE patients might be fundamental for the development of this complication. The aim of this study was to address the main clinical and immunological features associated with the development of infection and to create and validate a compound clinical-immunological infection predictive index in a cohort of SLE patients. We included 55 SLE patients with < 5 years since diagnosis. The clinical and immunological features were evaluated periodically and patients were followed-up during 1 year, searching for the development of infection. Immunophenotyping was performed by multiparametric flow cytometry and neutrophil extracellular traps (NETs) were assessed by confocal microscopy. Eighteen patients (32.7%) presented 19 infectious events, 5 (26.3%) were severe. For the construction of the index, we performed a logistic regression analysis and the cutoff points were determined with ROC curves. Increased numbers of peripheral Th17 cells, B cell lymphopenia, and lower TLR2 expression in monocytes, as well as the use of cyclophosphamide were the major risk factors for the development of infection and thus were included in the index. Besides, patients that developed infection were characterized by increased numbers of low-density granulocytes (LDGs) and higher expression of LL-37 in NETs upon infection. Finally, we validated the index retrospectively in a nested case-control study. A score >1.5 points was able to predict infection in the following year (AUC = 0.97; LR- = 0.001, specificity 100%, <i>P</i> = 0.0003). Our index encompasses novel immunological features able to prospectively predict the risk of infection in SLE patients.
Study Information
pubmed
2019
2019-01-14T00:00:00.000Z
10.3389/fimmu.2018.03144
31
50